Other transfer or payment: SIF Stream2- Growth
BioVectra Inc
$21,114,000.00
Increasing Canada’s Biopharmaceutical Receptor Capacity
FY 2017-18 · 2017-09-14
Summary
The project will increase BioVectra's contribution to medicine production capacity and support the research and development of advanced pharmaceutical products not currently manufactured in Canada.
Program
SIF Stream2- Growth
Recipient
Location
Charlottetown, Prince Edward Island, Canada
Recipient Type
For-profit organization
Business Number
101379949
Type
Other transfer or payment
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2017-09-14 | 2017-18 | $37,500,000.00 |
| 1 | 2017-09-14 | 2017-18 | $21,114,000.00 |
As published
Additional Information
The Amendment has been completed to reduce the contribution amount from $37.5M to $21.1M. This is a partially repayable contribution.
Additional Information (French)
La modification a été complétée afin de réduire le montant de la contribution de 37,5 M$ à 21,1 M$. Il s'agit d'une contribution partiellement remboursable.
Agreement End Date
2021-03-31
Agreement Number
811152
Agreement Start Date
2017-09-14
Agreement Title
Increasing Canada’s Biopharmaceutical Receptor Capacity
Agreement Title (French)
Accroître la capacité des récepteurs biopharmaceutiques du Canada
Agreement Type
Other transfer payment
Agreement Value
$21,114,000.00
Amendment Date
2021-02-01
Amendment Number
1
Description
The project will increase BioVectra's contribution to medicine production capacity and support the research and development of advanced pharmaceutical products not currently manufactured in Canada.
Description (French)
Le projet permettra non seulement d'augmenter la capacité de fabrication de médicaments de BioVectra, mais d'appuyer les activités de recherche et de développement liées à des produits pharmaceutiques de pointe qui ne sont pas fabriqués au Canada à l'heure actuelle.
Expected Results
This project will contribute to establishing Biovectra as a world leader in biologics development and production, grow the firm's market share and drive innovation and growth in Atlantic Canada Biotech Community. The project allows Biovectra to be positioned in the COVID-19 response while it continues to deliver on its significant economic, innovation and public benefit for Atlantic Canada. This project anticipates the creation of 200 new full-time jobs and will maintain 500 full-time jobs within Canada.
Expected Results (French)
Ce projet contribuera à faire de Biovectra un chef de file mondial du développement et de la production de produits biologiques, à accroître la part de marché de l'entreprise et à stimuler l'innovation et la croissance dans la communauté biotechnologique du Canada atlantique. Le projet permet à Biovectra de se positionner dans le cadre de la réponse à la COVID-19 tout en continuant à offrir d'importants avantages économiques, publics et liés à l'innovation pour le Canada atlantique. Ce projet prévoit la création de 200 nouveaux emplois à temps plein et le maintien de 500 emplois à temps plein au Canada.
Federal Riding
Kings--Hants
Federal Riding (French)
Kings--Hants
Federal Riding Number
12007
NAICS Code
325410
Organization Code
ic
Organization
Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada
Program Name
SIF Stream2- Growth
Program Name (French)
FIS Volet 2- Croissance
Program Purpose
-Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services;-Facilitate the growth and expansion of firms in Canada;-Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.
Program Purpose (French)
-favoriser les activités de R-D qui accéléreront le transfert de la technologie et la commercialisation de produits, de processus et de services novateurs ;-faciliter la croissance et l'expansion des entreprises au Canada ;-attirer et conserver des investissements de grande envergure au Canada ; et-faire progresser la recherche industrielle, le développement et la démonstration de technologies grâce à la collaboration entre les universitaires, les organisations à but non lucratif et le secteur privé.
Recipient Business Number
101379949
Recipient City
Charlottetown
Recipient Country
CA
Recipient Legal Name
BioVectra Inc
Recipient Operating Name
BioVectra Inc
Recipient Postal Code
C1E0A1
Recipient Province or Territory
PE
Recipient Type
F
Reference Number
033-2018-2019-Q4-811152
